Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Ravindra Uppaluri(Brigham and Women's Hospital), Douglas R. Adkins, Evisa Gjini(Brigham and Women's Hospital), Jessica Ley(Washington University in St. Louis), Ryan S. Jackson(Washington University in St. Louis), Jason T. Rich(Washington University in St. Louis), Vickie Y. Jo(Brigham and Women's Hospital), Rebecca D. Chernock(Washington University in St. Louis), Rachel Riley(University of Delaware), Erica K. Barnell(Washington University in St. Louis), Youstina Hanna(Princess Margaret Cancer Centre), Ann Marie Egloff(Brigham and Women's Hospital), Jonathan D. Schoenfeld(Brigham and Women's Hospital), Dorina Kallogjeri(Washington University in St. Louis), Jay F. Piccirillo(Washington University in St. Louis), Malachi Griffith(Washington University in St. Louis), Glenn J. Hanna(Dana-Farber Cancer Institute), Patrik Pipkorn(Washington University in St. Louis), Jason Kass(Brigham and Women's Hospital), Tenny Mudianto(New York University), Zachary L. Skidmore(James S. McDonnell Foundation), Iulia Cirlan(Princess Margaret Cancer Centre), Ana Lako(Brigham and Women's Hospital), Katie M. Campbell(University of California, Los Angeles), Brian Nussenbaum(Washington University in St. Louis), Tianxiang Lin(Washington University in St. Louis), Nicholas C. Spies(James S. McDonnell Foundation), Scott J. Rodig(Brigham and Women's Hospital), David T. Mulder(Princess Margaret Cancer Centre), Mackenzie Daly(Washington University in St. Louis), Randal C. Paniello, Trevor J. Pugh(Boston Children's Hospital), Wade L. Thorstad(Washington University in St. Louis), Gavin P. Dunn(Massachusetts General Hospital), Robert I. Haddad(Dana-Farber Cancer Institute), Hiram A. Gay(Washington University in St. Louis), Paul Zolkind(Washington University in St. Louis), Matthew D. Stachler(Brigham and Women's Hospital), Tiantian Li, Peter Oppelt(Washington University in St. Louis), Liye Zhou(Dana-Farber Cancer Institute), Obi L. Griffith(Washington University in St. Louis), Loren S. Michel(Memorial Sloan Kettering Cancer Center), Ian S. Hagemann(Washington University in St. Louis)
Cited by 14
Related Papers
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795